# US 2005/0238665 A1 · Soluble recombinant botulinum toxin proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0238665 A1
- Document ID: US20050238665A1
- Status: Published application
- Kind: A1
- Application number: 11/001,241
- Filed: 2004-11-30
- Published: 2005-10-27
- Earliest claimed: 1995-03-16
- Assignees: Allergan, Inc., Allergan Botox Limited
- Inventors: James Williams
- Web page: https://patentgrep.com/patent/US20050238665A1

## CPC

- C07K 14/33: from Clostridium (G)
- C07K 14/245: Escherichia (G)
- C07K 16/02: from eggs
- C07K 16/1282: Clostridium (G)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A soluble recombinant botulinum toxin, comprising the Clostridium botulinum a toxin amino acid sequence of SEQ ID NO:23, the toxin being obtained from an aerobic host cell by a process of recombinantly expressing the toxin using the aerobic host cell, the toxin being soluble.

### Claim 26 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, further comprising a poly-histidine tract.

### Claim 27 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, wherein the toxin comprises the amino acid sequence of SEQ ID NO:23.

### Claim 28 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, wherein the toxin is obtained from E. Coli bacteria.

### Claim 29 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, wherein the toxin is soluble in an aqueous environment.

### Claim 30 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, wherein the toxin exists in solution in the cytoplasm of the host cell.

### Claim 31 (depends on 25)

The soluble recombinant botulinum toxin of claim 25, wherein the toxin is soluble in a solution free of significant amounts of at least one of ionic detergents and denaturants.

### Claim 32 (depends on 25)

A composition comprising the soluble recombinant botulinum toxin of claim 25.
